InMode Ltd. (INMD)

NASDAQ: INMD · Real-Time Price · USD
13.56
+0.02 (0.11%)
Jun 8, 2026, 11:35 AM EDT - Market open
Market Cap858.83M -4.4%
Revenue (ttm)374.64M -4.5%
Net Income87.19M -50.4%
EPS1.36 -40.8%
Shares Out 63.36M
PE Ratio9.98
Forward PE9.88
Dividendn/a
Ex-Dividend Daten/a
Volume104,670
Open13.60
Previous Close13.54
Day's Range13.46 - 13.69
52-Week Range12.72 - 16.74
Beta1.93
AnalystsHold
Price Target14.33 (+5.72%)
Earnings DateMay 6, 2026

About INMD

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women’s health conditions and procedures. The ... [Read more]

Sector Healthcare
IPO Date Aug 8, 2019
Employees 660
Stock Exchange NASDAQ
Ticker Symbol INMD
Full Company Profile

Financial Performance

In 2025, InMode's revenue was $370.50 million, a decrease of -6.16% compared to the previous year's $394.82 million. Earnings were $93.83 million, a decrease of -48.24%.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for INMD stock is "Hold." The 12-month stock price target is $14.33, which is an increase of 5.72% from the latest price.

Price Target
$14.33
(5.72% upside)
Analyst Consensus: Hold
Stock Forecasts

News

InMode Transcript: Jefferies Global Healthcare Conference 2026

Management expects a flat revenue year amid market stabilization, with margin pressure from product mix and geographic shifts. New product launches, a specialized sales approach, and ongoing clinical studies aim to drive future growth, while capital allocation remains flexible.

4 days ago - Transcripts

InMode names Moshik Itzkovich as CFO, succeeding Yair Malca

InMode (INMD) announced the appointment of Dr. Shlomo Nass as Chairman of the company’s Board of Directors and Moshik Itzkovich as CFO, effective immediately. Moshik has held senior finance roles…

19 days ago - TheFly

InMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial Officer

YOKNEAM, Israel, May 20, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode" or the "Company"), a leading global provider of innovative medical technologies, today announced the appointment of D...

19 days ago - PRNewsWire

InMode to Present at Upcoming Investor Conferences and Events

YOKNEAM, Israel, May 13, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conf...

26 days ago - PRNewsWire

InMode price target lowered to $14 from $17 at Baird

Baird lowered the firm’s price target on InMode (INMD) to $14 from $17 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results and…

4 weeks ago - TheFly

InMode price target lowered to $19 from $21 at Barclays

Barclays lowered the firm’s price target on InMode (INMD) to $19 from $21 and keeps an Overweight rating on the shares.

4 weeks ago - TheFly

InMode reports Q1 adjusted EPS 25c, consensus 30c

Reports Q1 revenue $82.02M, consensus $79.86M. “While the macroeconomic environment remains challenging, our total revenue this quarter reached our expectations, however our profitability was lower th...

4 weeks ago - TheFly

InMode sees FY26 adjusted EPS $1.33-$1.38, consensus $1.45

Sees FY26 revenue $365M-$375M, consensus $370.04M. Non-GAAP gross margin between 74%-76%.

4 weeks ago - TheFly

InMode CFO Yair Malca steps down

Yair Malca has stepped down from his role as CFO, effective May 5. To support a smooth transition, Malca will remain engaged with the company in a consulting capacity for…

4 weeks ago - TheFly

InMode Earnings Call Transcript: Q1 2026

Q1 2026 revenue grew 5% year-over-year to $82M, led by U.S. strength, while gross margin declined due to product mix and higher expenses. Guidance for 2026 remains steady, with ongoing share buybacks and exploration of M&A as market competition intensifies.

4 weeks ago - Transcripts

InMode Earnings release: Q1 2026

InMode released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.

4 weeks ago - Filings

InMode Slides: Q1 2026

InMode has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.

4 weeks ago - Filings

InMode Reports First Quarter 2026 Financial Results: Quarterly GAAP Revenue of $82 Million, Represents 5% Year-Over-Year Increase

YOKNEAM, Israel, May 6, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for...

4 weeks ago - PRNewsWire

Weight-loss revolution sparks new appetite for aesthetics firms

Aesthetic firms are betting that a growing pool of patients experiencing loose skin and facial volume loss from GLP-1 obesity drugs will fuel a new wave of demand, as the sector heads into first-quart...

Other symbols: APYXEOLSESTA
5 weeks ago - Reuters

InMode Transcript: 25th Annual Needham Virtual Healthcare Conference

Q1 growth was driven by new product launches, but gross margins declined due to higher costs and increased competition. The company is expanding its product portfolio and international presence, while ongoing clinical studies and regulatory submissions target future growth. Guidance for 2026 remains cautious.

2 months ago - Transcripts

InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

Conference call to be held on Wednesday, May 6, 2026, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 13, 2026 /PRNewswire/ -- InMode Ltd.

2 months ago - PRNewsWire

InMode to Present at the 25th Annual Needham Virtual Healthcare Conference

YOKNEAM, Israel, March 24, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer an...

2 months ago - PRNewsWire

InMode Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Operations face ongoing disruptions in Israel, with manufacturing at 60% capacity and logistics strained. Over $600 million has been returned via buybacks, while M&A targets focus on complementary tech and Asia. Growth is expected to resume in 2027, supported by new products and organizational restructuring.

2 months ago - Transcripts

InMode announces new share repurchase program

InMode (INMD) announced that its Board of Directors has authorized a new share repurchase program for up to approximately 10% of the company’s total shares outstanding, representing approximately 6.38...

3 months ago - TheFly

InMode Announces New Share Repurchase Program

YOKNEAM, Israel, March 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that its Board of Directors has authorized a n...

3 months ago - PRNewsWire

InMode Transcript: Barclays 28th Annual Global Healthcare Conference

After two years of decline, expectations are for a flat top line in 2026, with organizational restructuring and new product launches aimed at supporting recovery. Margin pressures persist due to laser commoditization, but growth in new verticals and a focus on North America are key strategies.

3 months ago - Transcripts

InMode to Present at Upcoming Investor Conferences

YOKNEAM, Israel, Feb. 26, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor con...

3 months ago - PRNewsWire

InMode’s independent transaction committee determines to discontinue process

InMode (INMD) announced that the independent transaction committee of its Board of Directors has completed its review of proposals received in connection with a potential transaction. Following review...

3 months ago - TheFly

InMode Announces Conclusion of Independent Transaction Committee Review

YOKNEAM, Israel, Feb. 23, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) a leading global provider of innovative medical technologies ("InMode" or the "Company"), today announced that the independent...

3 months ago - PRNewsWire

InMode price target raised to $17 from $16 at Baird

Baird analyst Jeff Johnson raised the firm’s price target on InMode (INMD) to $17 from $16 and keeps a Neutral rating on the shares. The firm updated its model following…

4 months ago - TheFly